

Therapy of brain tumors by inhibition of nuclear receptor tailles (Tlx) (P-772)

Keywords

- Inhibition of Tlx inhibits tumor stem cell growth in neuronal tumors
- *in vivo* validated drug target for treating or preventing brain tumors
- Strong correlation between Tlx expression in neuronal tumors and survival in men

Abstract

DKFZ researchers identified nuclear receptor tailles (Tlx) as a valuable drug target for brain tumors especially glioblastomas. *In vivo* experiments showed almost doubling in survival time of mice harbouring brain tumors by inhibiting the expression of Tlx in tumor cells.

Development Stage

Tlx has been validated by *in vivo* models as a valuable drug target for brain tumors. In addition a highly significant correlation between expression of Tlx in brain tumor cells and survival of the patient was demonstrated.

Applications and Commercial Opportunity

DKFZ is looking for a partner for screening and developing a pharmaceutical inhibitor of nuclear receptor tailles.

Inventors

The investigators are: Schütz G. and Liu H. both DKFZ

Intellectual Property

A priority patent application was filed in Europe November 27, 2007 and published as [EP2065037](#). A PCT application was published as [WO 2009/068456](#), which was nationalized in USA (granted: [US8,404,657](#) and [US8,992,923](#) and pending: US14/620,836) and Europe (pending: [EP2219628](#)).

Further Information

No other public information is currently available, but further information (speaking with the inventor) is available under a signed Confidential Disclosure Agreement (CDA).

DKFZ Contact:

For further information, including a CDA, please contact:

Dr. Frieder Kern
Deutsches Krebsforschungszentrum
Technology Transfer Office T010
Email: F.Kern@dkfz.de
Tel.: +49-(0)6221-42-2952
Fax: +49-(0)6221-42-2956

Scientific Reference:

Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Zhu Z et al. [Cell Stem Cell. 2014 Aug 7;15\(2\):185-98.](#)

Figure:




Figure showing survival time of mice suffering from brain tumors in which Tlx has been knocked out or not after onset of disease by Cre-Lox technology.